Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

NCT05636436 PHASE1 ACTIVE_NOT_RECRUITING

The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.

Details

Lead sponsor	MAXVAX Biotechnology Limited Liability Company
Phase	PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	132
Start date	Wed Dec 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Herpes Zoster

Interventions

• Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
• High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
• Low dose adjuvant
• High dose adjuvant
• Positive control
• Placebo

Countries

China